Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response

被引:71
|
作者
von Locquenghien, Michelle [1 ]
Rozalen, Catalina [1 ]
Celia-Terrassa, Toni [1 ]
机构
[1] IMIM Hosp Mar Med Res Inst, Canc Res Program, Barcelona, Spain
来源
JOURNAL OF CLINICAL INVESTIGATION | 2021年 / 131卷 / 01期
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; TOLL-LIKE RECEPTORS; IFN-GAMMA; TUMOR-CELLS; DOWN-REGULATION; IMMUNE CHECKPOINTS; BONE METASTASIS; STEM-CELLS; E-CADHERIN; T-CELLS;
D O I
10.1172/JCI143296
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Interferons (IFNs) are pleiotropic cytokines critical for regulation of epithelial cell functions and for immune system regulation. In cancer, IFNs contribute to tumor-intrinsic and-extrinsic mechanisms that determine the quality of antitumor immunity and response to immunotherapy. In this Review, we focus on the different types of tumor IFN sensitivity that determine dynamic tumor-immune interactions and their coevolution during cancer progression and metastasis. We extend the discussion to new evidence supporting immunotherapy-mediated immunoediting and the dual opposing roles of IFNs that lead to immune checkpoint blockade response or resistance. Understanding the intricate dynamic responses to IFN will lead to novel immunotherapeutic strategies to circumvent protumorigenic effects of IFN while exploiting IFNmediated antitumor immunity.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Exosomes in cancer immunoediting and immunotherapy
    Zhao, Yarong
    Liu, Luotong
    Sun, Rongze
    Cui, Guilin
    Guo, Shuyu
    Han, Songren
    Li, Ziwei
    Bai, Tian
    Teng, Lesheng
    ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 17 (02) : 193 - 205
  • [2] Type I interferons and dendritic cells in cancer immunotherapy
    Sprooten, Jenny
    Agostinis, Patrizia
    Garg, Abhishek D.
    IMMUNOBIOLOGY OF DENDRITIC CELLS, PT A, 2019, 348 : 217 - 262
  • [3] Novel strategies for cancer immunotherapy: counter-immunoediting therapy
    Liu, Shaochuan
    Sun, Qian
    Ren, Xiubao
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [4] Cancer immunoediting and resistance to T cell-based immunotherapy
    O'Donnell, Jake S.
    Teng, Michele W. L.
    Smyth, Mark J.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (03) : 151 - 167
  • [5] OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy
    Leon-Letelier, Ricardo A.
    Bonifaz, Laura C.
    Fuentes-Panana, Ezequiel M.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2019, 105 (05) : 915 - 933
  • [6] Nanomedicine-Based Immunotherapy for the Treatment of Cancer Metastasis
    Zhang, Pengcheng
    Zhai, Yihui
    Cai, Ying
    Zhao, Yuliang
    Li, Yaping
    ADVANCED MATERIALS, 2019, 31 (49)
  • [7] Revisiting cancer immunoediting by understanding cancer immune complexity
    Manjili, Masoud H.
    JOURNAL OF PATHOLOGY, 2011, 224 (01): : 5 - 9
  • [8] microRNAs in the Antitumor Immune Response and in Bone Metastasis of Breast Cancer: From Biological Mechanisms to Therapeutics
    Gomarasca, Marta
    Maroni, Paola
    Banfi, Giuseppe
    Lombardi, Giovanni
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (08)
  • [9] Cancer Immunoediting in the Era of Immuno-oncology
    Gubin, Matthew M.
    Vesely, Matthew D.
    CLINICAL CANCER RESEARCH, 2022, 28 (18) : 3917 - 3928
  • [10] Cancer immunoediting hypothesis: history, clinical implications and controversies
    Lasek, Witold
    CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 47 (02) : 168 - 174